Table 2 Detection of SARS-CoV-2 RNAemia, N-antigenemia and anti-RBD IgG stratified by time since COVID-19 symptoms onset in critically ill patients.
Combination of qualitative results for SARS-CoV-2 RNAemia or N-antigenemia and anti-RBD IgGs (total no. of specimens) | Time evolved since symptoms onset | |||
|---|---|---|---|---|
Week 1. no. of specimens | Week 2. no. of specimens | Week 3. no. of specimens | ≥ Week 4. no. of specimens | |
Detection of viral RNAemia and anti-RBD IgG (n = 25) | 4 | 12 | 7 | 2 |
Detection of Detection of viral RNAemia and lack of anti-RBD IgG (n = 12) | 5 | 5 | 1 | 1 |
Absence of viral RNAemia and detection of anti-RBD IgG (n = 272) | 4 | 40 | 83 | 145 |
Absence of viral RNAemia and lack of anti-RBD IgG (n = 29) | 2 | 9 | 4 | 14 |
Detection of viral N-antigenemia and anti-RBD IgG (n = 24) | 6 | 16 | 0 | 2 |
Detection of viral N-antigenemia and lack of anti-RBD IgG (n = 19) | 6 | 9 | 2 | 2 |
Absence of viral N-antigenemia and detection of anti-RBD IgG (n = 273) | 2 | 36 | 90 | 145 |
Absence of viral N-antigenemia and lack of anti-RBD IgG (n = 22) | 1 | 5 | 3 | 13 |
